Cas:184839-29-0 2-[4-(2,6-difluorophenyl)-1,3-thiazol-2-yl]acetonitrile manufacturer & supplier

Chemical Name:2-[4-(2,6-difluorophenyl)-1,3-thiazol-2-yl]acetonitrile

CAS.NO:184839-29-0

Synonyms:[4-(2,6-difluorophenyl)thiazol-2-yl]acetonitrile;2-(4-(2,6-difluorophenyl)thiazol-2-yl)acetonitrile

Molecular Formula:C₁₁H₆F₂N₂S

Molecular Weight:236.24100

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:353.907ºC at 760 mmHg

Density:1.373

Index of Refraction:1.574

PSA:64.92000

Exact Mass:236.02200

LogP:3.15438

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like [4-(2,6-difluorophenyl)thiazol-2-yl]acetonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(4-(2,6-difluorophenyl)thiazol-2-yl)acetonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,[4-(2,6-difluorophenyl)thiazol-2-yl]acetonitrile Use and application,2-(4-(2,6-difluorophenyl)thiazol-2-yl)acetonitrile technical grade,usp/ep/jp grade.

Related News: Last month, Emergent Chief Executive Robert Kramer said it was his understanding that there are 100 million doses of J&J’s vaccine ready for FDA review and that regulators had begun the review process. 2-[4-(2,6-difluorophenyl)-1,3-thiazol-2-yl]acetonitrile manufacturer Active pharmaceutical ingredients directly impact disease. 2-[4-(2,6-difluorophenyl)-1,3-thiazol-2-yl]acetonitrile supplier Last month, Emergent Chief Executive Robert Kramer said it was his understanding that there are 100 million doses of J&J’s vaccine ready for FDA review and that regulators had begun the review process. 2-[4-(2,6-difluorophenyl)-1,3-thiazol-2-yl]acetonitrile vendor Last month, Emergent Chief Executive Robert Kramer said it was his understanding that there are 100 million doses of J&J’s vaccine ready for FDA review and that regulators had begun the review process. 2-[4-(2,6-difluorophenyl)-1,3-thiazol-2-yl]acetonitrile factory For Jefferies, this “has not been demonstrated to convincingly reduce Abeta plaque burden, in our view.” The firm forecasts $3 billion in global sales for gantenerumab, but at a striking 0%, “so probability so no contribution.”